Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Dec;172(6):1800-1806.
doi: 10.1016/j.surg.2022.08.022. Epub 2022 Oct 1.

A novel tool to predict nodal metastasis in small pancreatic neuroendocrine tumors: A multicenter study

Ammar A Javed  1 , Alessandra Pulvirenti  2 , Jian Zheng  3 , Theodoros Michelakos  4 , Yurie Sekigami  4 , Samrah Razi  5 , Caitlin A McIntyre  2 , Elizabeth Thompson  5 , David S Klimstra  2 , Vikram Deshpande  4 , Aatur D Singhi  3 , Matthew J Weiss  6 , Christopher L Wolfgang  7 , John L Cameron  5 , Alice C Wei  2 , Amer H Zureikat  3 , Cristina R Ferrone  4 , Jin He  8 ; Pancreatic Neuroendocrine Disease Alliance (PANDA)
Collaborators, Affiliations
Multicenter Study

A novel tool to predict nodal metastasis in small pancreatic neuroendocrine tumors: A multicenter study

Ammar A Javed et al. Surgery. 2022 Dec.

Abstract

Background: Nonfunctional pancreatic neuroendocrine tumors display a wide range of biological behavior, and nodal disease is associated with metastatic disease and poorer survival. The aim of this study was to develop a tool to predict nodal disease in patients with small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors.

Methods: A multicenter retrospective study was performed on patients undergoing resection for small nonfunctional pancreatic neuroendocrine tumors. Patients with genetic syndromes, metastatic disease at diagnosis, neoadjuvant therapy, or positive resection margin were excluded. Factors associated with nodal disease were identified to develop a predictive model. Internal validation was performed using bootstrap with 1,000 resamples.

Results: Nodal disease was observed in 39 (11.1%) of the 353 patients included. Presence of nodal disease was significantly associated with lower 5-year disease-free survival (71.6% vs 96.2%, P < .001). Two predictors were strongly associated with nodal disease: G2 grade (odds ratio: 3.51, 95% confidence interval: 1.71-7.22, P = .001) and tumor size (per mm increase, odds ratio: 1.14, 95% confidence interval: 1.03-1.25, P = .009). Adequate discrimination was observed with an area under the curve of 0.71 (95% confidence interval: 0.63-0.80). Based on risk distribution, 3 risk groups of nodal disease were identified; low (<5%), intermediate (≥5% to <20%), and high (≥20%) risk. The observed mean risk of nodal disease was 3.7% in the low-risk patients, 9.6% in the intermediate-risk patients, and 30.4% in the high-risk patients (P < .001). The 10-year disease-free survival in the low, intermediate, and high-risk groups was 100%, 88.8%, and 50.1%, respectively.

Conclusion: Our model using tumor grade and size can predict nodal disease in small nonfunctional pancreatic neuroendocrine tumors. Integration of this tool into clinical practice could help guide management of these patients.

PubMed Disclaimer

Publication types

Supplementary concepts